Actual status of therapeutic vaccination in non-small cell lung cancer

被引：6

作者：

Szyszka-Barth, Katarzyna ^{[1
]}

Ramlau, Katarzyna ^{[2
]}

Gozdzik-Spychalska, Joanna ^{[3
]}

Spychalski, Lukasz ^{[1
]}

Bryl, Maciej ^{[1
]}

Golda-Gocka, Iwona ^{[1
]}

Kopczynska, Anna ^{[4
]}

Barinow-Wojewodzki, Aleksander ^{[5
]}

Ramlau, Rodryg ^{[1
,6
]}

机构：

[1] Wielkopolska Ctr Pulmonol & Thoracosurg Eugenia &, Dept Clin Oncol, Diurnal Chemotherapy, Poznan, Poland

[2] Poznan Univ Med Sci, Clin Hosp, Poznan, Poland

[3] Poznan Univ Med Sci, Dept Pulmonol Allergol & Lung Oncol, Poznan, Poland

[4] Poznan Univ Med Sci, Dept Chemotherapy, Poznan, Poland

[5] Wielkopolska Ctr Pulmonol & Thoracosurg Eugenia &, Adult Pulm Rehabil Dept, Poznan, Poland

[6] Poznan Univ Med Sci, Thoracosurg Clin, Poznan, Poland

来源：

WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY | 2014年 / 18卷 / 02期

关键词：

non-small cell lung cancer; immunotherapy; vaccines;

D O I：

10.5114/wo.2014.42724

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Lung cancer is the leading cause of cancer-related death worldwide. Although treatment methods such as surgery, radiotherapy and/or chemotherapy have improved, prognosis remains unsatisfactory, and developing new therapeutic strategies is still an urgent matter. Immunotherapy is a novel therapeutic approach wherein activated immune cells can specifically kill tumour cells. Several lung cancer vaccines have demonstrated prolonged survival time in phase II and III trials, and several clinical trials are under investigation. However, many clinical trials involving cancer vaccination with defined tumour antigens have shown this method to work only in a small number of patients. Cancer immunotherapy is not completely effective in eradicating tumour cells because they evade host immune control.

引用

页码：77 / 84

页数：8

共 57 条

[1]

Acres B, 2009, J CLIN ONCOL, V27

[2] MUC1 mucin-mediated regulation of human T cells [J].

Agrawal, B ;

Longenecker, BM .

INTERNATIONAL IMMUNOLOGY, 2005, 17 (04) :391-399

[3]

Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5

[4] 1E10 anti-idiotype vaccine in non-small cell lung cancer -: Experience in stage IIIb/IV patients [J].

Alfonso, Saily ;

Diaz, Rosa M. ;

De la Torre, Ana ;

Santiesteban, Eduardo ;

Aguirre, Frank ;

Perez, Kirenia ;

Rodriguez, Jos L. ;

Barroso, Maria Del Carmen ;

Hernandez, Ana M. ;

Toledo, Darien ;

Gabri, Mariano R. ;

Alonso, Daniel F. ;

Viada, Carmen ;

Gomez, Roberto E. ;

Suarez, Eduardo ;

Vazquez, Ana M. ;

Perez, Rolando ;

Mocias, Amparo E. .

CANCER BIOLOGY & THERAPY, 2007, 6 (12) :1847-1852

[5]

[Anonymous], [No title captured]

[6] Immunotherapy for lung cancer [J].

Bradbury, Penelope A. ;

Shepherd, Frances A. .

JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) :S164-S170

[7] Harnessing the Immune System for the Treatment of Non-Small-Cell Lung Cancer [J].

Brahmer, Julie R. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (08) :1021-1028

[8] GSK's antigen-specific cancer immunotherapy programme: Pilot results leading to Phase III clinical development [J].

Brichard, Vincent G. ;

Lejeune, Diane .

VACCINE, 2007, 25 :B61-B71

[9]

Butts C, 2007, ANN ONCOL, V2, P38

[10]

Butts CA, 2013, J CLIN ONCOL S, V31, P7500

← 1 2 3 4 5 6 →